COMPARE · Reviewed July 2, 2026
CPRX vs HRMY
Verdict: Side-by-side breakdown using the Bull Rankings model. CPRX scored 84.4, HRMY scored 85 — HRMY ahead by 0.5999999999999943.
CPRX
Catalyst Pharmaceuticals, Inc.
84.4
$31.45
Score gap
0.5999999999999943
HRMY leads
HRMY
Harmony Biosciences Holdings, Inc.
85
$37.26
The companies
CPRXCatalyst Pharmaceuticals, Inc.
Why now
Biotechnology · market cap $3.9b. 3% off the 52-week high of $32.56. Revenue growing +20%, comfortably above the S&P median. PEG 0.92 — paying under fair value for the growth rate. 3 sell-side analysts publish a mean 1-yr target of $31.67 (implying +1% upside).
Moat
Net margin 37% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 22% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
HRMYHarmony Biosciences Holdings, Inc.
Why now
Biotechnology · market cap $2.2b. 9% off the 52-week high of $40.87. Revenue growing +22%, comfortably above the S&P median. PEG 0.70 — paying under fair value for the growth rate. 11 sell-side analysts rate this a Buy with a mean 1-yr target of $44.91 (implying +21% upside).
Moat
Net margin 16% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 16% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Base grades (each contributes ~14.3% of base composite)
| CPRX | Component | HRMY |
|---|---|---|
| C65 | FCF | C65 |
| B+85 | Rev | A-90 |
| A95 | D/E | B+85 |
| A-90 | P/E or P/S | A-90 |
| B+85 | PEG | A-90 |
| Supplemental signals · feed the score, not on the row card | ||
| B+85 | FCF Yield | A95 |
| A-90 | ROE | B+85 |
| 85.2 | Base composite | 86.4 |
Adjustments (signed deltas applied on top of base)
CPRX
compounder synergy (FCF yield ≥5% + ROE ≥15% + D/E <1)+4
GARP sweet spot (PEG <1, positive FCF)+1
forward P/E cheaper (18 → 10)+1
Total+6
HRMY
compounder synergy (FCF yield ≥5% + ROE ≥15% + D/E <1)+4
GARP sweet spot (PEG <1, positive FCF)+1
DCF cross-check (avg upside 314%)+2
Total+7
DCF cross-check (per-share value vs. live price)
| CPRX upside | Horizon | HRMY upside |
|---|---|---|
| -3% | 1Y | +190% |
| -6% | 5Y | +281% |
| -11% | 10Y | +471% |
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.